Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Yau, Thomas; Kang, Yoon‐Koo; Kim, Tae‐You; B. El-Khoueiry, Anthony; Santoro, Armando; Sangro, Bruno; Melero, Ignacio; Kudo, Masatoshi; Hou, Ming-Mo; Matilla, Ana; Tovoli, Francesco; J. Knox, Jennifer; Ruth He, Aiwu; F. El‐Rayes, Bassel; Acosta-Rivera, Mirelis; Lim, Ho-Yeong; Neely, Jaclyn; Shen, Yun; Wisniewski, Tami; Anderson, Jeffrey; Hsu, Chiun

doi:10.1001/jamaoncol.2020.4564

Public

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Published in JAMA Oncology • Oct 2, 2020

Authors:

Thomas Yau

Yoon‐Koo Kang

Tae‐You Kim

Abstract

IMPORTANCE: Most patients with hepatocellular carcinoma (HCC) are diagnosed with advanced disease not eligible for potentially curative therapies; therefore, new treatment options are needed. Combining nivolumab with ipilimumab may improve clinical outcomes compared with nivolumab monotherapy. OBJEC...

Subject

Medicine

Nivolumab

Ipilimumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!